Indian Researchers Discover Shared Biomarkers for Early Detection of Pancreatic and Glioma Cancers
Click to start listening
Synopsis
A team from the Institute of Nano Science and Technology in Mohali has discovered common metabolites in pancreatic and glioma cancers, paving the way for enhanced early diagnosis and improved treatment outcomes.
Key Takeaways
- Identification of common metabolites in pancreatic and glioma cancers.
- Potential for non-invasive early cancer diagnosis.
- Integration of advanced multi-technique approaches for comprehensive analysis.
- Insights into tumor microenvironment and cancer progression mechanisms.
- Development of targeted therapies to improve treatment efficacy.
New Delhi, Feb 20 (NationPress) A group of researchers from the Institute of Nano Science and Technology (INST) in Mohali -- an independent institute under the Department of Science and Technology (DST) -- has discovered common metabolites that are found in the difficult-to-detect pancreatic and glioma cancers. This discovery could enhance early diagnosis and improve treatment outcomes.
The team identified metabolites in exosomes obtained from pancreatic cancer, lung cancer, and glioma cancer cell lines, presenting a potential for universal biomarkers that could improve clinical applications.
According to the researchers, “This represents a promising non-invasive approach for early cancer diagnosis and therapeutic strategies.” Their findings appear in the journal Nanoscale.
Pancreatic and glioma cancers, known for their aggressive nature, are often detected at advanced stages, leading to poor prognoses. Therefore, there is an urgent need for reliable, non-invasive cancer biomarkers to fill the existing gaps in diagnostics and treatment, especially for these types of cancer that currently lack effective early detection methods.
Nano messengers (exosomes) serve as carriers of tumor-derived metabolites, offering a unique chance to study the tumor microenvironment (TME), as stated by the research team, which includes Nandini Bajaj and Dr. Deepika Sharma.
The researchers employed a multi-technique strategy that integrated Nanoparticle Tracking Analysis (NTA), Electron Microscopy (EM), Western Blot (WB), Fourier Transformed Infrared Spectroscopy (FTIR), untargeted Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), and Nuclear Magnetic Resonance (NMR). This approach provides an extensive characterization of exosomes, going beyond traditional single-method studies.
This research pushes the boundaries of cancer diagnostics, personalized medicine, and our comprehension of cancer progression mechanisms. The identified metabolites illuminate dysregulated pathways within the tumor microenvironment and offer insights into cancer progression, facilitating non-invasive and accurate cancer detection and targeted therapy.
The outcomes of this study could foster the development of targeted therapies aimed at disrupting the dysregulated metabolic pathways present in tumors, thereby enhancing treatment effectiveness and potentially minimizing side effects.
This breakthrough could greatly benefit patient outcomes, particularly through personalized, precision medicine strategies.
